大葉大學圖書館 |

Approaching China's pharmaceutical market[electronic resource] :a fundamental guide to clinical drug development /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
杜威分類號:	338.4761510951
書名/作者:	Approaching China's pharmaceutical market : a fundamental guide to clinical drug development // edited by Ming Q. Lu.
其他作者:	Lu, Ming Q.
出版者:	Cham : : Springer International Publishing :, 2015.
面頁冊數:	xvi, 648 p. : : ill., digital ;; 24 cm.
Contained By:	Springer eBooks
標題:	Pharmaceutical industry - China.
標題:	Drug development - China.
標題:	Biomedicine.
標題:	Pharmaceutical Sciences/Technology.
ISBN:	9783319155760 (electronic bk.)
ISBN:	9783319155753 (paper)
內容註:	Preface -- Law, Regulation and Guidance -- Pharmaceutical Intellectual Property Rights in China -- The China Food and Drug Administration (CFDA) -- Registration -- Guidance for Application Materials/Booklets (Chemical) -- New Investigational Drug Application -- Clinical Development of Investigational New Drug -- Strategic Drug Development in China and Surrounding Countries -- Drug Safety Monitoring and Reporting Systems in China -- In Vitro Diagnostic Development -- Index.
摘要、提要註:	This authoritative volume examines the major laws, regulations and guidelines related to pharmaceutical product development in China. With a focus on patent, clinical and registration strategies, the book helps Western companies introduce their clinical drugs to the Chinese market, determine a strategic path and bridge the gap for regulatory and legal differences between China and the Western world. For a better understanding of the drug registration process, it explores the differences between the China Food and Drug Administration (CFDA)--including its regulations and registration procedures--and those of the Western world. The volume discusses disparities between China's application requirements compared to Western standards to make it easier for companies to prepare their application packages. It also provides detailed commentary on CFDA guidelines in reference to clinical trial (IND) and market application (NDA) requirements. Overall, this book offers guidance for Western companies aspiring to expand into China's pharmaceutical market in hopes that they may gain a fundamental understanding of its rules and complexities in order to ensure a smooth transition and prevent future issues.
電子資源:	http://dx.doi.org/10.1007/978-3-319-15576-0

Approaching China's pharmaceutical market[electronic resource] :a fundamental guide to clinical drug development /
Approaching China's pharmaceutical marketa fundamental guide to clinical drug development /[electronic resource] :edited by Ming Q. Lu. - Cham :Springer International Publishing :2015. - xvi, 648 p. :ill., digital ;24 cm.

Preface -- Law, Regulation and Guidance -- Pharmaceutical Intellectual Property Rights in China -- The China Food and Drug Administration (CFDA) -- Registration -- Guidance for Application Materials/Booklets (Chemical) -- New Investigational Drug Application -- Clinical Development of Investigational New Drug -- Strategic Drug Development in China and Surrounding Countries -- Drug Safety Monitoring and Reporting Systems in China -- In Vitro Diagnostic Development -- Index.

This authoritative volume examines the major laws, regulations and guidelines related to pharmaceutical product development in China. With a focus on patent, clinical and registration strategies, the book helps Western companies introduce their clinical drugs to the Chinese market, determine a strategic path and bridge the gap for regulatory and legal differences between China and the Western world. For a better understanding of the drug registration process, it explores the differences between the China Food and Drug Administration (CFDA)--including its regulations and registration procedures--and those of the Western world. The volume discusses disparities between China's application requirements compared to Western standards to make it easier for companies to prepare their application packages. It also provides detailed commentary on CFDA guidelines in reference to clinical trial (IND) and market application (NDA) requirements. Overall, this book offers guidance for Western companies aspiring to expand into China's pharmaceutical market in hopes that they may gain a fundamental understanding of its rules and complexities in order to ensure a smooth transition and prevent future issues.

ISBN: 9783319155760 (electronic bk.)

Standard No.: 10.1007/978-3-319-15576-0doiSubjects--Topical Terms:

633034
Pharmaceutical industry
--China.

LC Class. No.: HD9672.C5

Dewey Class. No.: 338.4761510951

Approaching China's pharmaceutical market[electronic resource] :a fundamental guide to clinical drug development /
LDR:02673nam a2200313 a 4500 001 442855
003 DE-He213
005 20160218102747.0
006 m d
007 cr nn 008maaau
008 160715s2015 gw s 0 eng d
020 $a 9783319155760 (electronic bk.)
020 $a 9783319155753 (paper)
024 7 $a 10.1007/978-3-319-15576-0 $2 doi
035 $a 978-3-319-15576-0
040 $a GP $c GP
041 0 $a eng
050 4 $a HD9672.C5
072 7 $a TDCW $2 bicssc
072 7 $a MED072000 $2 bisacsh
082 0 4 $a 338.4761510951 $2 23
090 $a HD9672.C5 $b A652 2015
245 0 0 $a Approaching China's pharmaceutical market $h [electronic resource] : $b a fundamental guide to clinical drug development / $c edited by Ming Q. Lu.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2015.
300 $a xvi, 648 p. : $b ill., digital ; $c 24 cm.
505 0 $a Preface -- Law, Regulation and Guidance -- Pharmaceutical Intellectual Property Rights in China -- The China Food and Drug Administration (CFDA) -- Registration -- Guidance for Application Materials/Booklets (Chemical) -- New Investigational Drug Application -- Clinical Development of Investigational New Drug -- Strategic Drug Development in China and Surrounding Countries -- Drug Safety Monitoring and Reporting Systems in China -- In Vitro Diagnostic Development -- Index.
520 $a This authoritative volume examines the major laws, regulations and guidelines related to pharmaceutical product development in China. With a focus on patent, clinical and registration strategies, the book helps Western companies introduce their clinical drugs to the Chinese market, determine a strategic path and bridge the gap for regulatory and legal differences between China and the Western world. For a better understanding of the drug registration process, it explores the differences between the China Food and Drug Administration (CFDA)--including its regulations and registration procedures--and those of the Western world. The volume discusses disparities between China's application requirements compared to Western standards to make it easier for companies to prepare their application packages. It also provides detailed commentary on CFDA guidelines in reference to clinical trial (IND) and market application (NDA) requirements. Overall, this book offers guidance for Western companies aspiring to expand into China's pharmaceutical market in hopes that they may gain a fundamental understanding of its rules and complexities in order to ensure a smooth transition and prevent future issues.
650 0 $a Pharmaceutical industry $z China. $3 633034
650 0 $a Drug development $z China. $3 633035
650 1 4 $a Biomedicine. $3 463454
650 2 4 $a Pharmaceutical Sciences/Technology. $3 464319
700 1 $a Lu, Ming Q. $3 633033
710 2 $a SpringerLink (Online service) $3 463450
773 0 $t Springer eBooks
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-15576-0
950 $a Biomedical and Life Sciences (Springer-11642)